Wilms' tumor protein-1 (WT1) is over-expressed in a number of solid and hematologic malignancies including multiple myeloma. The emergence of WT1-specific T cells has been shown to correlate with better relapse-free survival after allogeneic stem cell transplantation in patients with hematologic malignancies.
Medical Director of the Cytotherapy Laboratory Guenther Koehne discusses the significance of WT1-specific cellular immune responses in patients with relapsed MM and high-risk cytogenetics who are undergoing allogeneic T-cell-depleted hematopoietic stem cell transplantation (TCD HSCT).
Findings suggest a correlation between the emergence of WT1-specific T cells post DLI and disease regression in patients being treated for relapsed MM. The present data supports the development of adoptive immunotherapeutic approaches utilizing WT1-specific T cells for patients with MM. These trials are currently being developed.